These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36588676)

  • 1. Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant
    Yu Z; Liu X; Du X; Chen H; Zhao F; Zhou Z; Wang Y; Zheng Y; Bergen PJ; Li X; Sun R; Fang L; Li W; Fan Y; Wu H; Guo B; Li J; Yu Y; Zhang J
    Front Pharmacol; 2022; 13():975066. PubMed ID: 36588676
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens.
    Bian X; Liu X; Hu F; Feng M; Chen Y; Bergen PJ; Li J; Li X; Guo Y; Zhang J
    Front Pharmacol; 2021; 12():785893. PubMed ID: 35058776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of polymyxin B regimens for the treatment of carbapenem-resistant organism nosocomial pneumonia: a real-world prospective study.
    Tang T; Li Y; Xu P; Zhong Y; Yang M; Ma W; Xiang D; Zhang B; Zhou Y
    Crit Care; 2023 Apr; 27(1):164. PubMed ID: 37106370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetic Modeling Using Polymyxin B Free Plasma Concentrations From Published Reports and Evaluation of Dosage Regimens Based on Monte Carlo Simulation in Critically Ill Patients.
    Zheng Y; Xu B; Chen S; Liu M; Huang H; Wang J; Wu X
    J Clin Pharmacol; 2023 Sep; 63(9):1036-1044. PubMed ID: 37125471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant
    Wang P; Liu S; Qi G; Xu M; Sun T; Yang J
    Front Microbiol; 2023; 14():1226981. PubMed ID: 37675417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of polymyxin B and proposed dosing regimens in elderly patients with multi-drug-resistant Gram-negative bacterial infections.
    Wang P; Liu D; Sun T; Zhang X; Yang J
    Int J Antimicrob Agents; 2022; 60(5-6):106693. PubMed ID: 36375775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patients.
    Hanafin PO; Kwa A; Zavascki AP; Sandri AM; Scheetz MH; Kubin CJ; Shah J; Cherng BPZ; Yin MT; Wang J; Wang L; Calfee DP; Bolon M; Pogue JM; Purcell AW; Nation RL; Li J; Kaye KS; Rao GG
    Clin Microbiol Infect; 2023 Sep; 29(9):1174-1181. PubMed ID: 37217076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Empiric Polymyxin B Treatment of Patients Infected with Gram-Negative Organisms Detected Using a Blood Antimicrobial Surveillance Network in China.
    Wu X; Huang C; Wang H; Ji J; Ying C; Xiao Y
    Drug Des Devel Ther; 2021; 15():2593-2603. PubMed ID: 34168431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of different antimicrobial regimens in carbapenem-resistant
    Sun WM; Zhou H; Shen LS; Yang Q; Ma WJ; Zhou JY
    Zhonghua Nei Ke Za Zhi; 2019 Aug; 58(8):566-571. PubMed ID: 31365977
    [No Abstract]   [Full Text] [Related]  

  • 10. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China.
    Zou D; Yao G; Shen C; Ji J; Ying C; Wang P; Liu Z; Wang J; Jin Y; Xiao Y
    Front Microbiol; 2021; 12():738812. PubMed ID: 34899628
    [No Abstract]   [Full Text] [Related]  

  • 12. Population pharmacokinetic analysis, renal safety, and dosing optimization of polymyxin B in lung transplant recipients with pneumonia: A prospective study.
    Cai XJ; Chen Y; Zhang XS; Wang YZ; Zhou WB; Zhang CH; Wu B; Song HZ; Yang H; Yu XB
    Front Pharmacol; 2022; 13():1019411. PubMed ID: 36313312
    [No Abstract]   [Full Text] [Related]  

  • 13. Population pharmacokinetics of polymyxin B in critically ill patients receiving continuous venovenous haemofiltration.
    Wang P; Xing H; Zhang F; Liu S; Lu Y; Zhang X; Yang J; Sun T
    Int J Antimicrob Agents; 2022 Jul; 60(1):106599. PubMed ID: 35526750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Polymyxin B in Obese Patients for Resistant Gram-Negative Infections.
    Wang P; Zhang Q; Feng M; Sun T; Yang J; Zhang X
    Front Pharmacol; 2021; 12():754844. PubMed ID: 34880755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infections.
    Dubrovskaya Y; Chen TY; Scipione MR; Esaian D; Phillips MS; Papadopoulos J; Mehta SA
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5394-7. PubMed ID: 23959321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Therapeutic Drug Monitoring of Polymyxin B During Continuous Renal Replacement Therapy in Two Pediatric Patients: Do Not Underestimate Extracorporeal Clearance.
    Xu C; Liu X; Cui Y; Huang X; Wang Y; Fan Y; Wu H; Li X; Guo B; Zhang J; Zhang Y
    Front Pharmacol; 2022; 13():822981. PubMed ID: 35401193
    [No Abstract]   [Full Text] [Related]  

  • 17. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Epidemiology and Risk Factors of Carbapenem-Resistant Klebsiella Pneumoniae Bloodstream Infections in Wuhan, China.
    Liu C; Liu L; Jin MM; Hu YB; Cai X; Wan L; Zhang HY; Li RY; Wu XJ
    Curr Med Sci; 2022 Feb; 42(1):68-76. PubMed ID: 34985611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic properties of polymyxin B in Escherichia coli and Klebsiella pneumoniae murine infection models.
    van der Meijden A; Aranzana-Climent V; van der Spek H; de Winter BCM; Couet W; Meletiadis J; Muller AE; van den Berg S
    J Antimicrob Chemother; 2023 Mar; 78(3):832-839. PubMed ID: 36718051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of polymyxin B and dosage strategy in critically ill patients with/without continuous renal replacement therapy.
    Luo X; Zhang Y; Liang P; Zhu H; Li M; Ding X; Zhang J
    Eur J Pharm Sci; 2022 Aug; 175():106214. PubMed ID: 35609779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.